If you were hot and bothered by the progeny of ALK-tyrosine kinase inhibitors (TKI) outpacing EGFR-TKIs, calm down. A third-generation EGFR-TKI has arrived, and it goes by the name osimertinib. A recent phase 3 trial reported in NEJM declares it to confer a progression-free-survival advantage over the older versions (e.g. gefitinib) in untreated advanced non-small cell lung cancer patients. Yes, this probably counts as one of the soft end-points we just alluded to, but the still immature overall survival results look like they’ll mature into ones that will make us proud.